NCBiotech News

NCBiotech provided a $250,000 loan to bootstrap CasTag BioSciences, a Duke spinout based on a technology that marks proteins in an entirely new way, using the genome-editing tool CRISPR. The resulting products are selling, and the potential is HiUGE.

Greensboro's Kepley BioSystems has developed a natural liquid called K9 Strategic Scent Stimulant to help dogs avoid distraction while you're socially distancing on COVID-era walks.

A LabCorp blood test that helps identify individuals who’ve been exposed to the COVID-19 coronavirus is now broadly available.

Audentes Therapeutics, a San Francisco company whose name changed to Astellas Gene Therapies on March 31, 2021, announced plans for a $109.4 million, 209-employee gene therapy production facility in Sanford, a short distance from a $600 million Pfizer gene therapy campus under construction.

Grifols, a global biotherapeutics company with major operations in North Carolina, has begun producing the first specific COVID-19 drug at its manufacturing campus in Clayton.

Raleigh's Collaborations Pharmaceuticals is partnering with universities, foundations and other companies to develop drugs that treat rare and neglected diseases, but it's also targeting COVID-19 now. 

Appalachian State University faculty members have developed a free app to allow people around the world log the activity of bees and other pollinators.

NC Med Tech Firm BioMedInnovations Gets FDA OK for Innovative COVID-19 Ventilator Developed wIth Rare Partnerships, from NASCAR to Lawrence Livermore

Grifols, a global biotherapeutics company with more than 2,000 employees in North Carolina, is adding 300 more to its Clayton workforce as part of a $351.6 million expansion there.

A transformative Belgian crop protection company, Biotalys NV, is establishing U.S. headquarters in Research Triangle Park.

Cary-based startup Atom Bioworks plans to use artificial intelligence and nanotechnology, boosted by a $240K NSF grant, to design a rapid diagnostic for COVID-19.

NCBiotech portfolio company Arrevus has landed two federal grants totaling roughly $800,000 to investigate its novel chaperone protein inhibitor, ARV-1502, ​for treating sepsis and for wound healing.

Morrisville's Q2 Solutions has inked a partnership deal with Thermo Fisher Scientific tol speed up enrollment of patients in oncology clinical trials.

A grant to help train military service members in North Carolina and Texas for biopharmaceutical manufacturing careers has been approved by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).

The U.S. Army has selected Metabolon for a five-year contract to analyze the metabolic profiles of military personnel.